MacroGenics Inc., a clinical-stage biopharmaceutical company, has entered into a royalty purchase agreement with Sagard Healthcare Partners. Under this agreement, MacroGenics received a $70 million upfront cash payment from Sagard in exchange for a capped royalty interest on future global net sales of ZYNYZ, a PD-1 inhibitor originally developed by MacroGenics. This strategic partnership is expected to extend MacroGenics' cash runway through the first half of 2027, supported by the upfront payment, projected future payments from partners, and anticipated cost-saving measures. MacroGenics will continue to retain its other economic interests related to ZYNYZ and support a portion of its global commercial manufacturing needs.